1. Home
  2. FUSB vs TENX Comparison

FUSB vs TENX Comparison

Compare FUSB & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First US Bancshares Inc.

FUSB

First US Bancshares Inc.

SELL

Current Price

$17.10

Market Cap

91.4M

Sector

Finance

ML Signal

SELL

TENX

Tenax Therapeutics Inc.

SELL

Current Price

$1.48

Market Cap

81.1M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
FUSB
TENX
Founded
1952
1967
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
91.4M
81.1M
IPO Year
1995
2001

Fundamental Metrics

Financial Performance
Metric
FUSB
TENX
Price
$17.10
$1.48
Analyst Decision
Buy
Analyst Count
0
10
Target Price
N/A
★ $10.29
AVG Volume (30 Days)
2.9K
★ 1.5M
Earning Date
10-28-2026
11-05-2026
Dividend Yield
★ 1.66%
N/A
EPS Growth
★ N/A
N/A
EPS
★ 1.00
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$16.80
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$12.81
$1.31
52 Week High
$16.99
$19.40

Technical Indicators

Market Signals
Indicator
FUSB
TENX
Relative Strength Index (RSI) 65.89 34.99
Support Level $15.75 $1.34
Resistance Level N/A $2.01
Average True Range (ATR) 0.19 0.14
MACD 0.05 0.01
Stochastic Oscillator 71.02 4.46

Price Performance

Historical Comparison
FUSB
TENX

About FUSB First US Bancshares Inc.

First US Bancshares Inc is a bank holding company. The Bank conducts general commercial banking business and offers banking services such as demand, savings, individual retirement accounts, and time deposits, personal and commercial loans, safe deposit box services, and remote deposit capture. The Bank provides a range of commercial banking services to small and medium-sized businesses, property managers, business executives, professionals, and other individuals.

About TENX Tenax Therapeutics Inc.

Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.

Share on Social Networks: